Heparin and the atherosclerotic process.
D000818:Animals; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy / Q000503:physiopathology*; D001777:Blood Coagulation / Q000187:drug effects; D001792:Blood Platelets / Q000502:physiology; D002455:Cell Division; D055598:Chemical Phenomena; D002627:Chemistry, Physical; D003167:Complement Activation / Q000187:drug effects; D004727:Endothelium / Q000187:drug effects; D011464:Epoprostenol / Q000502:physiology; D005342:Fibrinolysis; D006493:Heparin / Q000494:pharmacology* / Q000502:physiology / Q000627:therapeutic use; D006801:Humans; D008071:Lipoprotein Lipase / Q000378:metabolism; D008075:Lipoproteins, HDL / Q000502:physiology; D012157:Mononuclear Phagocyte System / Q000502:physiology; D009130:Muscle, Smooth / Q000166:cytology; D013917:Thrombin / Q000502:physiology; D014280:Triglycerides / Q000097:blood
D008075:Lipoproteins, HDL; D014280:Triglycerides; D006493:Heparin; D011464:Epoprostenol; D008071:Lipoprotein Lipase; D013917:Thrombin